Ryu Kariywasam-Chavez graduated from Kean University in Union, New Jersey in May 2025 with a bachelor of arts in film/television and multimedia. Ryu joined Pharmacy Times as a content associate in April of 2026.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead author of the phase 3 STArT trial and professor of pediatrics and emergency medicine at Emory University School of Medicine, discusses findings from the phase 3 STArT trial of intravenous arginine for acute sickle cell pain, limitations of time to crisis resolution as a clinical trial end point, and opportunities for pharmacists to improve opioid-use data collection.
August 2026 brought major oncology advances, including new FDA approvals and pivotal phase 3 data that expanded targeted, immune-based, and personalized treatment strategies.
August 2026 brought first-in-class approvals in multiple myeloma, warm autoimmune hemolytic anemia, and polycythemia vera alongside important findings involving bispecific antibodies, sickle cell pain, and infection risk.
Suzetrigine postoperative pain data grows, but buprenorphine access gaps persist; naloxone patch and sickle cell pain trial reshape nonopioid care.
Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens.
Early-phase trial data showed antitumor activity in heavily pretreated metastatic colorectal cancer.
Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in patients with previously untreated advanced biliary tract cancer.
CK0803 is an investigational allogeneic cord blood–derived regulatory T-cell therapy designed to target neuroinflammation in amyotrophic lateral sclerosis.
Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.
The FDA has expanded the approval of dolutegravir expands access to a second-generation integrase inhibitor for infants in the neonatal period.
The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.
The FDA has granted fast track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.
The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.
The FDA granted fast track designation to safusidenib, an investigational oral IDH1 inhibitor that produced durable responses in a phase 2 study of patients with treatment-naive grade 2 IDH1-mutant glioma.
A nationwide study found that Black pregnant patients initiating buprenorphine had a 69% higher adjusted risk of treatment discontinuation during pregnancy than White patients.
Following community reports of more than 400 cancer cases in Keyport and Union Beach, New Jersey officials are expanding environmental sampling near a former landfill.
Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival over pembrolizumab alone.
The patch detected fentanyl and automatically delivered dose-responsive naloxone in laboratory and mouse studies, offering a potential strategy for addressing unwitnessed opioid overdoses.
A nationally representative analysis found serologic immunity to hepatitis A and B was limited among US adults, including populations at elevated risk.
In an interview with Pharmacy Times, Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discussed how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.
First-line trastuzumab deruxtecan significantly delayed disease progression in HER2-mutant advanced NSCLC.
The all-oral combination of osimertinib and savolitinib significantly improved progression-free and overall survival following osimertinib resistance.
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.
The FDA's decision makes iberdomide the first approved CELMoD for patients with relapsed/refractory multiple myeloma.
Active surveillance increased from 27% in 2005 to 93% in 2024, reflecting a major shift away from immediate treatment for favorable-risk disease.
The warning has prompted new CDC recommendations for prevention and molecular diagnostic testing.
The combination also produced a 78.6% complete response rate in heavily pretreated patients with R/R mantle cell lymphoma following BTK inhibitor therapy.
Phase 3 MajesTEC-9 findings show teclistamab monotherapy significantly improves progression-free survival and overall survival compared with PVd or Kd.
The designation highlights an emerging strategy targeting TNFR2-mediated immune suppression in heavily pretreated platinum-resistant ovarian cancer.
A phase 4 study found that a suzetrigine-based multimodal pain regimen provided favorable postoperative pain control, with 76.1% of patients recovering without opioid rescue medication.
